Trial Profile

The safety and efficacy of STC3141 in patient with COVID-19 ARDS require intensive care

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STC 314 (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections
Focus Adverse reactions; Therapeutic Use
Sponsors Grand Medical Pty Ltd.

Most Recent Events

30 Jul 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
28 May 2020 New trial record
06 May 2020 According to a China Grand Pharmaceutical and Healthcare Holdings Limited Grand Medical Pty Ltd, a wholly-owned subsidiary of the Group and a new drug research center established in Australia is approved to conduct this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com